SearcharxivSearch

arXiv subjects

Marta Fiocco

Publications and source records attributed to Marta Fiocco.

6 recordsLinked to original sources

Discrimination performance in illness-death models with interval-censored disease data

In clinical studies, the illness-death model is often used to describe disease progression. A subject starts disease-free, may develop the disease and then die, or die directly. In clinical practice, disease can only be diagnosed at pre-specified follow-up visits, so the exact time of disease onset is often unknown, resulting in interval-censored data. This study examines the impact of ignoring this interval-censored nature of disease data on the discrimination performance of illness-death models, focusing on the time-specific Area Under the receiver operating characteristic Curve (AUC) in both incident/dynamic and cumulative/dynamic definitions. A simulation study with data simulated from Weibull transition hazards and disease state censored at regular intervals is conducted. Estimates are derived using different methods: the Cox model with a time-dependent binary disease marker, which ignores interval-censoring, and the illness-death model for interval-censored data estimated with three implementations - the piecewise-constant model from the msm package, the Weibull and M-spline models from the SmoothHazard package. These methods are also applied to a dataset of 2232 patients with high-grade soft tissue sarcoma, where the interval-censored disease state is the post-operative development of distant metastases. The results suggest that, in the presence of interval-censored disease times, it is important to account for interval-censoring not only when estimating the parameters of the model but also when evaluating the discrimination performance of the disease.

stat.ME

A general approach to fitting multistate cure models based on an extended-long-format data structure

A multistate cure model is a statistical framework used to analyze and represent the transitions individuals undergo between different states over time, accounting for the possibility of being cured by initial treatment. This model is particularly useful in pediatric oncology where a proportion of the patient population achieves cure through treatment and therefore will never experience certain events. Despite its importance, no universal consensus exists on the structure of multistate cure models. Our study provides a novel framework for defining such models through a set of non-cure states. We develops a generalized algorithm based on the extended long data format, an extension of the traditional long data format, where a transition can be divided into two rows, each with a weight assigned reflecting the posterior probability of its cure status. The multistate cure model is built upon the current framework of multistate model and mixture cure model. The proposed algorithm makes use of the Expectation-Maximization (EM) algorithm and weighted likelihood representation such that it is easy to implement with standard packages. Additionally, it facilitates dynamic prediction. The algorithm is applied on data from the European Society for Blood and Marrow Transplantation (EBMT). Standard errors of the estimated parameters in the EM algorithm are obtained via a non-parametric bootstrap procedure, while the method involving the calculation of the second-derivative matrix of the observed log-likelihood is also presented.

stat.ME

A multiple imputation approach to distinguish curative from life-prolonging effects in the presence of missing covariates

Medical advances have increased cancer survival rates and the possibility of finding a cure. Hence, it is crucial to evaluate the impact of treatments both in terms of cure and prolongation of survival. To achieve this, we may use a Cox proportional hazards (PH) cure model. However, a significant challenge in applying such a model is the potential presence of partially observed covariates. We aim to refine the methods for imputing partially observed covariates based on multiple imputation and fully conditional specification (FCS) approaches. To be more specific, we consider a general case in which different covariate vectors are used to model the probability of cure and the survival of patients who are not cured. We investigated the performance of the multiple imputation procedure based on the exact conditional distribution and an approximate imputation model, which helps to draw imputed values at a lower computational cost. To assess the effectiveness of these approaches, we compare them with a complete case analysis and an analysis that includes all available covariates in modelling both cure probabilities and the survival of the uncured. We discuss the application of these techniques to a real-world dataset from the BO06 clinical trial on osteosarcoma.

stat.ME

Causal effect of chemotherapy received dose intensity on survival outcome: a retrospective study in osteosarcoma

This study aims to analyse the effects of reducing Received Dose Intensity (RDI) in chemotherapy treatment for osteosarcoma patients on their survival by using a novel approach. In this scenario, toxic side effects are risk factors for mortality and predictors of future exposure levels, introducing post-assignment confounding. Chemotherapy administration data from BO03 and BO06 Randomized Clinical Trials (RCTs) in ostosarcoma are employed to emulate a target trial with three RDI-based exposure strategies: 1) standard, 2) reduced, and 3) highly-reduced RDI. Investigations are conducted between subgroups of patients characterised by poor or good Histological Responses (HRe). Inverse Probability of Treatment Weighting (IPTW) is first used to transform the original population into a pseudo-population which mimics the target randomized cohort. Then, a Marginal Structural Cox Model with effect modification is employed. Conditional Average Treatment Effects (CATEs) are ultimately measured as the difference between the Restricted Mean Survival Time of reduced/highly-reduced RDI strategy and the standard one. Confidence Intervals for CATEs are obtained using a novel IPTW-based bootstrap procedure. Significant effect modifications based on HRe were found. Increasing RDI-reductions led to contrasting trends for poor and good responders: the higher the reduction, the better (worsen) was the survival in poor (good) reponders. This study introduces a novel approach to (i) comprehensively address the challenges related to the analysis of chemotherapy data, (ii) mitigate the toxicity-treatment-adjustment bias, and (iii) repurpose existing RCT data for retrospective analyses extending beyond the original trials' intended scopes.

stat.AP

SUrvival Control Chart EStimation Software in R: the success package

Monitoring the quality of statistical processes has been of great importance, mostly in industrial applications. Control charts are widely used for this purpose, but often lack the possibility to monitor survival outcomes. Recently, inspecting survival outcomes has become of interest, especially in medical settings where outcomes often depend on risk factors of patients. For this reason many new survival control charts have been devised and existing ones have been extended to incorporate survival outcomes. The R package success allows users to construct risk-adjusted control charts for survival data. Functions to determine control chart parameters are included, which can be used even without expert knowledge on the subject of control charts. The package allows to create static as well as interactive charts, which are built using ggplot2 (Wickham 2016) and plotly (Sievert 2020).

stat.AP

Longitudinal Latent Overall Toxicity (LOTox) profiles in osteosarcoma: a new taxonomy based on latent Markov models

Due to the presence of multiple types of adverse events with different levels of severity, the analysis of longitudinal toxicity data is a difficult task in cancer studies. In this work, a novel approach based on latent Markov models and compositional data techniques is proposed. The latent status of interest is the Latent Overall Toxicity (LOTox) condition of each patient. The main objectives consist in identifying different latent states of overall toxicity burden and investigating the evolution of individual toxicity risk during cancer treatment. This methodology is applied to osteosarcoma treatment data to provide novel techniques that may support medical decisions in childhood cancer therapy.

stat.AP